Symptomatic intracranial hemorrhage after intravenous thrombolysis in ischemic stroke: prediction and treatment

Alteplase intravenous thrombolysis is the most effective drug treatment for acute ischemic stroke at present. Hemorrhagic transformation after thrombolysis, especially symptomatic intracranial hemorrhage (sICH), will seriously affect the outcomes after intravenous thrombolysis, and even threaten the life of patients. Therefore, the prediction and treatment of sICH after intravenous thrombolysis is particularly important. This article reviews the prediction and treatment of sICH after intravenous thrombolysis. Key words: Stroke; Brain Ischemia; Thrombolytic Therapy; Cerebral Hemorrhage; Intracranial Hemorrhages; Tissue Plasminogen Activator; Administration, Intravenous; Risk Assessment